EUCTR2017-000364-15-NL进行中（未招募）1 期
A randomized phase II/III study of pulsatile high-dose sunitinib versus TAS-102 in patients with metastatic colorectal carcinoma (mCRC). - SUNRISE-CRC
VU University Medical Center, Department of Medical0 个研究点目标入组 60 人开始时间: 2019年9月11日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •To be eligible for this trial, patients will need to meet all of the following inclusion criteria. Screening must be performed no more than 14 days prior to the first study drug dose.
- •1: Signed (by the patient or legally acceptable representative) and dated Informed Consent Form (ICF).
- •2: Histological or cytological confirmed, documentation of incurable locally advanced or metastatic, colorectal adenocarcinoma, not amenable for potentially curative treatment (i.e. inoperable).
- •3: Indication for treatment with TAS-102; progressive on (or intolerant to) therapy including fluoropyrimidine, irinotecan, oxaliplatin, anti-VEGF therapy and anti-EGFR therapy (for tumours with wild-type KRAS)).
- •4: Evaluable disease by RECIST version 1.1 criteria (see appendix III).
- •6: Age = 18 years.
- •7: Eastern Cooperative Oncology Group (ECOG) Performance Status of < 3.
- •8: Normal 12-lead ECG (clinically insignificant abnormalities permitted).
- •9: No signs of clinical thyroid abnormalities (suppletion or blocking drugs permitted).
- •10: Adequate bone marrow function; hemoglobin > 5.6 mmol/l, absolute neutrophil count (ANC) >1,5 x 10*9/l, Platelet count ? 100 x 10*9/l,
- •11: Adequate liver function; total bilirubin < 1.5 times the upper limit of normal (ULN), ALT and AST < 2.5 x ULN (In case of liver metastases: < 5 x ULN).
- •12: Albumin higher than 25 g/L
- •13: Serum creatinine <1.5 x ULN or creatinine clearance ? 50 ml/min/1.73m2 (based on MDRD).
- •14: Pregnant or breast-feeding subjects: Women of childbearing potential must have a negative pregnancy test performed within 7 days of the start of treatment. For fertile men or women of childbearing potential: documented willingness to use a highly effective means of contraception (e.g., hormonal methods [implants, injectables, or combined oral contraceptives], intrauterine devices, sexual abstinence, or vasectomized or surgically sterilized partner). Contraception is necessary for at least 6 months after receiving the study medication.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 30
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 30
排除标准
- •The following criteria exclude the patient from enrollment in this trial
- •1: Previous treatment with sunitinib and/or TAS-102 for mCRC.
- •2: Evidence of significant uncontrolled concomitant disease, such as cardiovascular disease (including stroke, New York Heart Association Class III or IV cardiac disease or myocardial infarction within 6 months prior to screening, unstable arrhythmia, clinically significant valvular heart disease and unstable angina); pulmonary disease (including obstructive pulmonary disease > GOLD 2 and inadequately treated symptomatic bronchospasm), and uncontrolled central nervous system, renal, hepatic, endocrine, or gastrointestinal disorders; or a serious non-healing wound or fracture.
- •3: Extensive prior radiotherapy in the rectum, pelvis or in more than 3 vertebrae in the spine (less than 3 vertebrae are considered a small radiation field and eligibility will be decided on an individual basis from the PI).
- •4: Poorly controlled hypertension despite adequate blood pressure medication. Blood pressure must be =160/95 mmHg at the time of screening on a stable antihypertensive regimen. Blood pressure must be stable on at least 2 separate measurements.
- •5: Instable seizure disorders requiring anticonvulsant therapy.
- •6: Major surgery, other than diagnostic surgery, within 4 weeks prior to day 1, without complete recovery.
- •7: Uncontrolled bleeding disorders, and/or active bleeding.
- •8: Known active bacterial, viral, fungal, mycobacterial, or other infection. (including HIV and atypical mycobacterial disease, but excluding fungal infection of the nail beds.)
- •9: Known hypersensitivity to sunitinib, TAS-102, or to its excipients.
- •10: Presence of any significant psychiatric disorder(s) that would interfere with the patient’s compliance.
- •11: Chemotherapy, radiotherapy, or other anti-cancer therapy within the previous 4 weeks; no nitrosoureas or mitomycin C within the previous 6 weeks; no investigational agents within the previous 4 weeks.
- •12: Clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis.
- •13: Untreated or active central nervous system (CNS) metastases.
- •14: Predisposing colonic or small bowel disorders in which the symptoms are uncontrolled as indicated by baseline of > 3 loose stools daily despite medication.
- •15: Unresolved bowel obstruction
- •16: Any evidence of a disease or condition that might affect compliance with the protocol or interpretation of the study results or render the patient at high risk from treatment complications.
研究者
相似试验
招募中
2 期
A randomized phase II study of pulsatile high-dose sunitinib versus TAS-102 in patients with metastatic colorectal carcinoma (mCRC).metastatic colorectal carcinoma1001799010017991NL-OMON53126Radboud Universitair Medisch Centrum70
招募中
不适用
A randomized phase II study of pulsatile high-dose sunitinib versus TAS-102 in patients with metastatic colorectal carcinoma (mCRC).NL-OMON27160Radboud UMC60
已完成
不适用
Randomised phase II study of sequentially high dose Methotrexate and Fluorouracil combined with Epirubicin (FEMTX) versus FEMTX plus Cisplatin (FEMTX-P) in advanced gastric cancerOesophagus, Stomach CancerMalignant neopplasm of other or ill-defined digestive organsCancerISRCTN69546136Pharmacia Ltd & Upjohn (UK)
尚未招募
不适用
A phase II/III study of high-dose, intermittent sunitinib in patients with recurrent glioblastoma multiforme: the STELLAR studyBrain cancerGlioblastoomHersentumorGlioomGliomaGlioblastoma multiformeGBMBrain tumorNL-OMON21711VU University Medical Center100
进行中（未招募）
1 期
A trial testing an alternative high-dose, intermittend scheduling for sunitinib in patients with recurrent brain cancer- Glioblastoma multiforme (GBM)- GlioblastomaEUCTR2016-001797-15-NLVU University Medical Center, Department of Medical Oncology100